Bank of New York Mellon Corp Raises Position in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Bank of New York Mellon Corp lifted its stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO - Free Report) by 35.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 418,820 shares of the company's stock after buying an additional 109,762 shares during the quarter. Bank of New York Mellon Corp owned about 0.33% of Organogenesis worth $1,340,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Rhumbline Advisers increased its stake in Organogenesis by 7.1% in the fourth quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock valued at $369,000 after acquiring an additional 7,621 shares during the last quarter. State Street Corp raised its position in Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company's stock worth $4,175,000 after purchasing an additional 9,090 shares during the last quarter. Captrust Financial Advisors acquired a new position in shares of Organogenesis in the third quarter worth approximately $36,000. Intech Investment Management LLC bought a new stake in shares of Organogenesis in the 3rd quarter valued at $43,000. Finally, SG Americas Securities LLC boosted its position in Organogenesis by 66.4% during the fourth quarter. SG Americas Securities LLC now owns 41,746 shares of the company's stock valued at $134,000 after acquiring an additional 16,660 shares during the last quarter. Institutional investors and hedge funds own 49.57% of the company's stock.

Organogenesis Stock Down 0.6 %

NASDAQ:ORGO traded down $0.03 on Thursday, hitting $4.67. The stock had a trading volume of 567,217 shares, compared to its average volume of 1,093,241. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a 52 week low of $2.17 and a 52 week high of $6.71. The business's fifty day moving average is $4.16 and its 200 day moving average is $3.56. The company has a market cap of $592.29 million, a PE ratio of -77.83 and a beta of 1.66.

Remove Ads

Analysts Set New Price Targets

Separately, Morgan Stanley boosted their price target on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th.

Insider Buying and Selling at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 36.90% of the company's stock.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.